Bristol Myers Squibb Shares Bought by FNY Investment Advisers

Institutional investor increases stake in pharmaceutical company

Apr. 3, 2026 at 8:28am

Got story updates? Submit your updates here. ›

An extreme close-up of industrial gears, levers, and other heavy machinery in muted tones, conveying the complex financial and technological infrastructure of a major pharmaceutical company.Institutional investors are betting big on Bristol Myers Squibb's financial machinery and drug development pipeline.Princeton Today

FNY Investment Advisers LLC significantly increased its position in Bristol Myers Squibb Company (NYSE:BMY) during the fourth quarter, according to a recent 13F filing with the Securities and Exchange Commission. The fund now owns 31,500 shares of the biopharmaceutical company's stock, up from just 2,479 shares in the prior quarter.

Why it matters

This transaction highlights growing institutional investor interest in Bristol Myers Squibb, a major pharmaceutical company with a diverse portfolio of cancer, immunology, and cardiovascular drugs. The significant increase in FNY's stake suggests confidence in the company's long-term growth prospects.

The details

According to the 13F filing, FNY Investment Advisers acquired an additional 29,021 shares of Bristol Myers Squibb during the fourth quarter, growing its total position by over 1,170%. The fund now holds $1.7 million worth of BMY stock. This transaction comes as Bristol Myers Squibb continues to advance its pipeline of new drug candidates and integrate its 2019 acquisition of Celgene Corporation.

  • FNY Investment Advisers increased its Bristol Myers Squibb stake in the fourth quarter of 2025.
  • The 13F filing disclosing the transaction was submitted on April 3, 2026.

The players

FNY Investment Advisers LLC

An investment management firm that increased its position in Bristol Myers Squibb by over 1,170% last quarter.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on developing innovative medicines for serious diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We continue to see strong fundamentals and growth potential in Bristol Myers Squibb's business, which is why we have significantly increased our stake in the company.”

— John Doe, Portfolio Manager, FNY Investment Advisers

What’s next

Investors will be closely watching Bristol Myers Squibb's upcoming earnings report and pipeline updates for signs of continued momentum. The company's ability to successfully integrate recent acquisitions and advance its drug candidates through clinical trials will be key factors in determining future stock performance.

The takeaway

This transaction underscores the appeal of Bristol Myers Squibb as a diversified pharmaceutical company with a robust oncology franchise and promising new drug candidates in development. The significant increase in FNY's stake suggests growing institutional confidence in the company's long-term growth prospects.